Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Immunotherapy and Brain Metastatic Lung Cancer

April 13th 2020

PD-L1 Less Than 49%: Available Treatments

April 13th 2020

Progression on Immunotherapy: Treatment Approach

April 13th 2020

Therapy Approach for PD-L1 Over 50% Lung Cancer

April 13th 2020

Work-Up and Management of Nondriver Metastatic Lung Cancer

April 13th 2020

New Frontier for Genomics: Radiotherapy in Early Breast Cancer

April 8th 2020

By individualizing risk of locoregional recurrence and radiosensitivity with molecular subtyping/genomic classifiers, it is hoped that use and/or extent of adjuvant radiation therapy could be tailored in early-stage breast cancer.

Dr. Marshall on the Push Toward Precision Medicine in CRC

April 8th 2020

John L. Marshall, MD, discusses the push toward precision medicine in colorectal cancer.

FDA Grants Pembrolizumab Priority Review for TMB-High Tumors

April 7th 2020

The FDA has granted a priority review designation to pembrolizumab for the treatment of patients with unresectable or metastatic solid tumors with tissue tumor mutational burden-high status.

Dr. Otterson on When to Start Immunotherapy in NSCLC

April 7th 2020

Gregory A. Otterson, MD, discusses when to start treatment with immunotherapy in patients with non–small cell lung cancer.

Dr. Levy on Emerging Biomarkers and Corresponding Therapies in Lung Cancer

April 4th 2020

Benjamin P. Levy, MD, discusses emerging biomarkers and their respective therapies in lung cancer.

ctDNA Provides Prognostic and Predictive Value in Early-Stage Breast Cancer

April 3rd 2020

Circulating tumor DNA can be used as a predictive measure of response to neoadjuvant chemotherapy and inform overall prognosis in patients with early-stage breast cancer, providing information that can be used to tailor treatment.

Dr. Hamid on the Evolution of Precision Medicine in Prostate Cancer

April 3rd 2020

Anis Hamid, MBBS, genitourinary oncology research fellow, Dana-Farber Cancer Institute, discusses the evolution of precision medicine in prostate cancer.

New Era of CDK Targeting Gets Rolling in Oncology

April 2nd 2020

Serving as gatekeepers at the entry to the cell cycle, CDK4 and CDK6 make ideal therapeutic targets to block the unchecked proliferation that is a hallmark of cancer cells.

Immunotherapy Biomarker Testing Depends on Tumor Type

April 1st 2020

A Working Group of the European Society for Medical Oncology has determined that a decision tree on the sequential use of different tests in immunotherapy decision-making cannot be a general one for all cancers but should be designed on the basis of the specific tumor type.

Expert Discusses Tissue Versus Liquid Biopsy in Next-Generation Sequencing in Lung Cancer

April 1st 2020

Lynette M. Sholl, MD, discusses the evolving use of liquid and tissue biopsies for next-generation sequencing in the treatment paradigm for patients with lung cancer.

Pennell Shares Best Practices for Molecular Testing in Lung Cancer

March 31st 2020

Nathan Pennell, MD, PhD, offers strategies regarding molecular testing in patients with lung cancer and how to address treatment if patients are symptomatic and molecular testing results are unavailable.

The Future of Treatment for Soft Tissue Diseases

March 25th 2020

GIST Treatment: Durability of Response and Challenges

March 25th 2020

Use of Targeted Therapy in GIST Mutations

March 25th 2020

Targeted Therapy Advancements in Sarcoma Subtypes

March 25th 2020